drugset / Trial / NCT01833169
BKM120 for Patients With PI3K-activated Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this signal seeking study was is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
Timeline
- Start
- 2013-03-29
- Primary completion
- 2016-09-26
- Completion
- 2016-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buparlisib | Small molecule | 100 mg | Oral |
Indications
No indication recorded.